| Revenue growth | 17% FY26 growth, significantly outpacing IPM growth of 8.6%. |
|---|---|
| Margins | FY26 EBITDA margin improved 80bps to 20.9% despite Q4 employee costs. |
| Demand visibility | Strong in chronic/semi-chronic segments, now contributing 72% of revenue. |
| Management confidence | High; consistently outperforming industry growth rates at nearly 2x. |
Growth
FY26 revenue grew 17% to ₹1,403cr; PAT surged 33% to ₹199cr. Q4 revenue grew 20.2% YoY.
Outlook
Guided 15%+ organic revenue growth and 20%+ PAT growth for FY27; commissioning hormone plant in Q1/Q2 FY27.
Risks
Potential margin impact from rising API costs due to oil prices; integration risks of new divisions.
Earnings Call filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,117.70
- Market cap
- ₹12,952 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 65.1×Sector 50.4×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 3.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
Corona Remedies Price Movement Clarification
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies Earnings Call Transcript: Key Takeaways
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
- Call
- Guides 20% growth
Corona Remedies Investor Presentation: Key Takeaways
Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.
Corona Remedies Q1 FY27 Results: Net Profit ₹60.1 Cr, Up 30.1% YoY
Corona Remedies Ltd reported revenue from operations of ₹422.4 Cr (+21.9% YoY) and net profit of ₹60.1 Cr (+30.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹60.1 Cr · +30.1% YoY
Corona Remedies Earnings Call: Key Takeaways
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.